Free Trial
NASDAQ:PLYX

Polaryx Therapeutics (PLYX) Stock Price, News & Analysis

Polaryx Therapeutics logo
$1.77 -0.11 (-5.85%)
Closing price 11/13/2026 03:56 PM Eastern
Extended Trading
$1.84 +0.07 (+3.95%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Polaryx Therapeutics Stock (NASDAQ:PLYX)

Advanced

Key Stats

Today's Range
$1.77
▼
$1.88
50-Day Range
$1.73
▼
$2.15
52-Week Range
$1.69
▼
$48.91
Volume
10,404 shs
Average Volume
22,442 shs
Market Capitalization
$88.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.67
Consensus Rating
Moderate Buy

Company Overview

Polaryx Therapeutics is a biotechnology company focused on developing treatments for rare genetic diseases. Its research and development activities target conditions with significant unmet medical needs, including disorders that affect the nervous system and metabolism.

The company’s work centers on advancing drug candidates for these conditions. Publicly available information about its specific products, commercial operations, geographic reach and leadership is limited.

AI Generated. May Contain Errors.

Polaryx Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

PLYX MarketRank™: 
1.874835828735 of 5 stars

Polaryx Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 710th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Polaryx Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Polaryx Therapeutics has a consensus price target of $7.67, representing about 333.1% upside from its current price of $1.77.

  • Amount of Analyst Coverage

    Polaryx Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Polaryx Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Polaryx Therapeutics are expected to decrease in the coming year, from ($0.20) to ($0.28) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Polaryx Therapeutics is -22.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Polaryx Therapeutics is -22.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Polaryx Therapeutics has a P/B Ratio of 17.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.51% of the float of Polaryx Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Polaryx Therapeutics has a short interest ratio ("days to cover") of 6.48.
  • Change versus previous month

    Short interest in Polaryx Therapeutics has recently increased by 16.88%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Polaryx Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Polaryx Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Polaryx Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Polaryx Therapeutics this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Polaryx Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    45.82% of the stock of Polaryx Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Polaryx Therapeutics has minimal institutional ownership at this time.

  • Read more about Polaryx Therapeutics' insider trading history.
Receive PLYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Polaryx Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PLYX Stock News Headlines

HC Wainwright Issues Optimistic Forecast for PLYX Earnings
A free stock pick, from me to you
Elon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.tc pixel
See More Headlines

PLYX Stock Analysis - Frequently Asked Questions

Polaryx Therapeutics' stock was trading at $2.61 on February 20, 2026. Since then, PLYX shares have decreased by 32.2% and is now trading at $1.77.

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) released its quarterly earnings data on Thursday, November, 12th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02.

Polaryx Therapeutics (PLYX) raised $0 in an initial public offering (IPO) on the week of February 2nd 2026. The company issued 47,343,297 shares at a price of $0.00 per share.

Shares of PLYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/12/2026
Today
11/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PLYX
CIK
2075320
Fax
N/A
Employees
11
Year Founded
2014

Price Target and Rating

High Price Target
$10.00
Low Price Target
$6.00
Potential Upside/Downside
+333.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.53
Quick Ratio
13.53

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.10 per share
Price / Book
17.70

Miscellaneous

Outstanding Shares
49,850,000
Free Float
27,007,000
Market Cap
$88.23 million
Optionable
N/A
Beta
N/A

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:PLYX) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners